Switch theme
Sign up to access all valuation multiples
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
2017
10
LTM Revenue $9.8M
LTM EBITDA n/a
-$35.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Kronos Bio has a last 12-month revenue of $9.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Kronos Bio achieved revenue of $9.8M and an EBITDA of -$61.7M.
Kronos Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Kronos Bio valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $6.3M | $9.8M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$120M | -$61.7M | XXX | XXX | XXX |
| EBITDA Margin | -1904% | -627% | XXX | XXX | XXX |
| Net Profit | -$133M | -$113M | XXX | XXX | XXX |
| Net Margin | -2118% | -1144% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Kronos Bio's stock price is $1.
Kronos Bio has current market cap of $52.3M, and EV of -$35.2M.
See Kronos Bio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$35.2M | $52.3M | XXX | XXX | XXX | XXX | $-1.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Kronos Bio has market cap of $52.3M and EV of -$35.2M.
Kronos Bio's trades at -3.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Kronos Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Kronos Bio and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$35.2M | XXX | XXX | XXX |
| EV/Revenue | -3.6x | XXX | XXX | XXX |
| EV/EBITDA | 0.6x | XXX | XXX | XXX |
| P/E | -0.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKronos Bio's NTM/LTM revenue growth is -100%
Kronos Bio's revenue per employee for the last fiscal year averaged $1.0M, while opex per employee averaged $7.3M for the same period.
Over next 12 months, Kronos Bio's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Kronos Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Kronos Bio and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 57% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -627% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -48% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.0M | XXX | XXX | XXX | XXX |
| Opex per Employee | $7.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 250% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 494% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 744% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Kronos Bio acquired XXX companies to date.
Last acquisition by Kronos Bio was XXXXXXXX, XXXXX XXXXX XXXXXX . Kronos Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Kronos Bio founded? | Kronos Bio was founded in 2017. |
| Where is Kronos Bio headquartered? | Kronos Bio is headquartered in United States of America. |
| How many employees does Kronos Bio have? | As of today, Kronos Bio has 10 employees. |
| Who is the CEO of Kronos Bio? | Kronos Bio's CEO is Dr. Deborah Knobelman, PhD. |
| Is Kronos Bio publicy listed? | Yes, Kronos Bio is a public company listed on NAS. |
| What is the stock symbol of Kronos Bio? | Kronos Bio trades under KRON ticker. |
| When did Kronos Bio go public? | Kronos Bio went public in 2020. |
| Who are competitors of Kronos Bio? | Similar companies to Kronos Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Kronos Bio? | Kronos Bio's current market cap is $52.3M |
| What is the current revenue of Kronos Bio? | Kronos Bio's last 12-month revenue is $9.8M. |
| What is the current EV/Revenue multiple of Kronos Bio? | Current revenue multiple of Kronos Bio is -3.6x. |
| What is the current revenue growth of Kronos Bio? | Kronos Bio revenue growth between 2023 and 2024 was 57%. |
| Is Kronos Bio profitable? | Yes, Kronos Bio is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
